The results of the current study, which focused on a number of individual components of clinical response, demonstrated that patients with ET who are refractory to or intolerant of hydroxyurea can achieve clinically meaningful and durable reductions in platelet and WBC counts and improvements in ET-related symptoms with ruxolitinib treatment.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Rumi E;Cazzola M;
2017-01-01

Abstract

The results of the current study, which focused on a number of individual components of clinical response, demonstrated that patients with ET who are refractory to or intolerant of hydroxyurea can achieve clinically meaningful and durable reductions in platelet and WBC counts and improvements in ET-related symptoms with ruxolitinib treatment.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1321726
Citazioni
  • ???jsp.display-item.citation.pmc??? 23
  • Scopus 46
  • ???jsp.display-item.citation.isi??? ND
social impact